Komori
Share Issuance and Disposal4882Perseus Proteomics Inc.Pharmaceuticals

Notice Regarding the Finalization of the Terms of the Stock-Based Compensation Stock Options (Share Acquisition Rights)

The previously undetermined allottees, allocation amounts, total number and number of underlying shares for the equity compensation-type stock options resolved on 15 April 2026 have been finalized. A total of 1,201 options, representing 120,100 underlying shares, will be allocated to 3 executive officers and 29 employees.

Worth reading
35Immaterial
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
120100
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of stock compensation-type stock options (stock acquisition rights)

発行・処分する株式数

120,100 common shares (1,201 share subscription rights)

Intended allottee
Category The Company's executive officers (excluding those elected as directors of the Company) / Number of Employees 3 / Number allocated 280, Category The Company's employees / Number of Employees 29 people / Number allocated 921
Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total number issued: 1,201; number of unexercised rights: Not disclosed
Categories and Number of Persons Covered
Category The Company's executive officers (excluding those elected as directors of the Company) / Number of Employees 3 / Number of allocated shares Equivalent to 28,000 shares, Category The Company's employees / Number of Employees 29 people / Number of allocated shares Equivalent to 92,100 shares
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of stock compensation-type stock options (stock acquisition rights)
Number of shares to be issued or disposed of120,100 common shares (1,201 share subscription rights)
Intended allotteeCategory The Company's executive officers (excluding those elected as directors of the Company) / Number of Employees 3 / Number allocated 280, Category The Company's employees / Number of Employees 29 people / Number allocated 921
Number of Stock Acquisition RightsTotal number issued: 1,201; number of unexercised rights: Not disclosed
Categories and Number of Persons CoveredCategory The Company's executive officers (excluding those elected as directors of the Company) / Number of Employees 3 / Number of allocated shares Equivalent to 28,000 shares, Category The Company's employees / Number of Employees 29 people / Number of allocated shares Equivalent to 92,100 shares
Items this document does not state (23)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To issue equity compensation-type stock options to the Company's executive officers and employees.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Finalization of the Terms of the Stock-Based Compensation Stock Options (Share Acquisition Rights) | Perseus Proteomics Inc. (4882) timely disclosure | Komori